Biogen and Neomorph Collaborate to Discover and Develop Molecular Glue Degraders (MGD)
Shots:
- Biogen and Neomorph collaborate to discover and develop MGD for Alzheimer’s, rare neurological, and immunological diseases using Neomorph's proprietary molecular glue discovery platform
- Under the agreement, both companies will collaborate on small molecule degraders for key targets, with Biogen advancing clinical candidates. Neomorph will receive an upfront payment and milestone payments as the collaboration progresses, including contingent milestones, pre-clinical milestones, and certain clinical, regulatory, commercial, and sales milestones totaling up to $1.45B
- Biogen will cover certain research development costs, and Neomorph may also earn future royalties in the mid-single to low-double-digit range
Ref: Biogen | Image: Biogen & Neomorph
Related News:- For an Aggregate of $1.8B, Biogen Acquires Human Immunology Biosciences to Strengthen its Immunology Portfolio
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
